Evidence map›Paper›PMID 32210264›Full record

ArticleScientific reports2020

A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer.

Robin Myte, Sophia Harlid, Anneli Sundkvist, Björn Gylling, Jenny Häggström, Carl Zingmark, Anna Löfgren Burström, Richard Palmqvist, Bethany Van Guelpen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robin MyteDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. robin.myte@umu.se.ORCID http://orcid.org/0000-0002-2974-2003
Sophia HarlidDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-8540-6891
Anneli SundkvistDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Björn GyllingDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Jenny HäggströmDepartment of Statistics, Umeå School of Business, Economics, and Statistics, Umeå University, Umeå, Sweden.
Carl ZingmarkDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Anna Löfgren BurströmDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Richard PalmqvistDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-9692-101X
Umeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Body fatness increases the risk of colorectal cancer (CRC). Insulin resistance and altered adipokines are potential mechanisms, but previous biomarker studies have been inconsistent. Intertumoral heterogeneity might provide an explanation. We investigated insulin, C-peptide, adiponectin, and leptin in relation to CRC molecular subtypes using a nested case-control design (1010 cases, 1010 matched controls, median 12.3 years from baseline to CRC diagnosis) from the population-based Northern Sweden Health and Disease Study. Repeated samples were available from 518 participants. Risks of CRC and subtypes, defined by tumor BRAF and KRAS mutations and microsatellite instability (MSI) status, were estimated using conditional logistic regression and linear mixed models. Higher C-peptide and lower adiponectin were associated with increased CRC risk (odds ratios per standard deviation increase (95% CI): 1.11 (1.01, 1.23) and 0.91 (0.83, 1.00), respectively), though weakened when adjusted for body mass index. Insulin and leptin were not associated with CRC risk. Within-individual time trajectories were similar in cases and controls, and no subtype-specific relationships were identified (all P

Indexed as

AdiponectinAdultAgedBiomarkersCase-Control StudiesColorectal NeoplasmsC-PeptideFemaleHumansInsulinLeptinLongitudinal StudiesMaleMicrosatellite InstabilityMiddle AgedMutationAdiponectinADIPOQ protein, humanBiomarkersBRAF protein, humanC-PeptideInsulinKRAS protein, humanLEP protein, humanLeptinProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID32210264
PMCPMC7093429
OpenAlexW3013742768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.